{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:20:36Z","timestamp":1779099636503,"version":"3.51.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,18]]},"DOI":"10.7759\/cureus.109083","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T09:48:36Z","timestamp":1779097716000},"source":"Crossref","is-referenced-by-count":0,"title":["Vitiligo-Like Hypopigmentation Induced by Ribociclib in a Patient With Metastatic Breast Cancer"],"prefix":"10.7759","author":[{"given":"Israe","family":"El Ghazouli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Gallouj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ouiame","family":"El Jouari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05914-w","article-title":"Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors","volume":"185","author":"Sollena P","year":"2021","unstructured":"Sollena P, Nikolaou V, Soupos N, et al.. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. Breast Cancer Res Treat. 2021, 185:247-53. 10.1007\/s10549-020-05914-w","journal-title":"Breast Cancer Res Treat"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01071-1","article-title":"Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: a systematic review","volume":"44","author":"Silvestri M","year":"2021","unstructured":"Silvestri M, Cristaudo A, Morrone A, et al.. Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: a systematic review. Drug Saf. 2021, 44:725-32. 10.1007\/s40264-021-01071-1","journal-title":"Drug Saf"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1067264","article-title":"Case report: vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response","volume":"13","author":"Pasqualoni M","year":"2023","unstructured":"Pasqualoni M, Orlandi A, Palazzo A, et al.. Case report: vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response. Front Oncol. 2023, 13:1067264. 10.3389\/fonc.2023.1067264","journal-title":"Front Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi GN","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, et al.. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016, 375:1738-48. 10.1056\/NEJMoa1609709","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf123","article-title":"Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4\/6 inhibitors and endocrine therapy","volume":"30","author":"Jacobs F","year":"2025","unstructured":"Jacobs F, Gaudio M, Andreottola C, et al.. Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4\/6 inhibitors and endocrine therapy. Oncologist. 2025, 30:oyaf123. 10.1093\/oncolo\/oyaf123","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83513","article-title":"Vitiligo-like depigmentation induced by cyclin-dependent kinase 4\/6 inhibitors in the treatment of metastatic breast cancer: a case report and literature review","volume":"17","author":"Lee CY","year":"2025","unstructured":"Lee CY, Tang-Lin L, Beh SY. Vitiligo-like depigmentation induced by cyclin-dependent kinase 4\/6 inhibitors in the treatment of metastatic breast cancer: a case report and literature review. Cureus. 2025, 17:e83513. 10.7759\/cureus.83513","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13050158","article-title":"A vitiligo-like cutaneous reaction induced by ribociclib in advanced breast cancer: an unusual case report from Colombia","volume":"13","author":"Montenegro JF","year":"2025","unstructured":"Montenegro JF, Rivas-Tafurt GP, Vidal-Ca\u00f1as S, et al.. A vitiligo-like cutaneous reaction induced by ribociclib in advanced breast cancer: an unusual case report from Colombia. Diseases. 2025, 13:158. 10.3390\/diseases13050158","journal-title":"Diseases"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.ijp_85_23","article-title":"Photoallergic dermatitis and vitiligo-like lesion in a patient with metastatic breast cancer using ribociclib","volume":"55","author":"Mente\u015fo\u011flu D","year":"2023","unstructured":"Mente\u015fo\u011flu D. Photoallergic dermatitis and vitiligo-like lesion in a patient with metastatic breast cancer using ribociclib. Indian J Pharmacol. 2023, 55:190-1. 10.4103\/ijp.ijp_85_23","journal-title":"Indian J Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_239_2024","article-title":"Ribociclib induced vitiligo-like lesions","volume":"91","author":"Kothari R","year":"2025","unstructured":"Kothari R, Darling HS, Bhatnagar A, Janney M, Mohan S, Kumar R. Ribociclib induced vitiligo-like lesions. Indian J Dermatol Venereol Leprol. 2025, 91:396-7. 10.25259\/IJDVL_239_2024","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf123","article-title":"Vitiligo-like leucoderma following cyclin-dependent kinase 4 and 6 inhibitor treatment: systematic review of the literature","volume":"50","author":"Markowitz ME","year":"2025","unstructured":"Markowitz ME, Levitt JA, Merose R, et al.. Vitiligo-like leucoderma following cyclin-dependent kinase 4 and 6 inhibitor treatment: systematic review of the literature. Clin Exp Dermatol. 2025, 50:1598-605. 10.1093\/ced\/llaf123","journal-title":"Clin Exp Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/420765-vitiligo-like-hypopigmentation-induced-by-ribociclib-in-a-patient-with-metastatic-breast-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T09:48:37Z","timestamp":1779097717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/420765-vitiligo-like-hypopigmentation-induced-by-ribociclib-in-a-patient-with-metastatic-breast-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.109083","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}